天津医药

• 论著 • 上一篇    下一篇

CEA、NSE及CYFRA21-1与非小细胞肺癌术后病理分期的相关性研究

李志1,孙大强1,王晓东2   

  1. 1. 天津医科大学附属胸科医院
    2. 天津医科大学研究生院
  • 收稿日期:2011-10-24 修回日期:2012-03-07 出版日期:2012-06-15 发布日期:2012-06-15
  • 通讯作者: 孙大强

Correlation of CEA、NSE、CYFRA21-1 and Pathological Staging with Postoperative Non-Small Cell Lung Cancer

  • Received:2011-10-24 Revised:2012-03-07 Published:2012-06-15 Online:2012-06-15

PDF (PC)

2964

摘要： 摘要 目的: 研究CEA、NSE及CYFRA21-1三种肿瘤标志物在非小细胞肺癌中的联合表达，探讨其与可手术的非小细胞肺癌患者术后病理分期的相关性。方法: 收集143例非小细胞肺癌患者的术后病理资料，所有患者术前均检测血清中CEA、NSE及CYFRA21-1的浓度，分析其表达结果与术后病理分期之间的关系。结果：血清CEA、CYFRA21-1的浓度在不同的T、N分期及淋巴结转移组数不同（N1单组转移和N2单组转移与N2多组转移）的患者中均有差异（P＜0.05或P＜0.01），有统计学意义；血清NSE浓度只在不同的T分期（T1与T3）有统计学差异（P＜0.05），而在不同病理N分期之间无显著性差异（P＞0.05）。结论 ：术前检测非小细胞肺癌患者血清CEA、CYFRA21-1的浓度对准确判断非小细胞肺癌分期有重要的临床意义。

关键词: 非小细胞肺癌, 病理分期, 癌胚抗原, 细胞角蛋白19片段, 神经元特异性烯醇化酶

Abstract: Abstract Objective： To investigate the union expression of CEA、NSE and CYFRA21-1 in non-small cell lung cancer and to explore the relationship between the tumor markers and pathological staging of non-small cell lung cancer. Methods: 143 patients in non-small cell lung cancer with their postoperative pathological dates were collected .The expression results of CEA、NSE and CYFRA21-1 were measured before operation in all patients and then were used to study the correlation between them and postoperative pathological staging . Results: The levels of serum CEA and CYFRA21-1 in patients are different when T、N stages and group numbers of metastasis lymphnodes are not same (P＜0.05orP＜0.01).Levels in patients of N2 with multi- metastasis groups lymphnodes were significantly higher than those in patients of N1 and N2 with single-metastasis group lymphnode . The levels of serum NSE in patients of different T stages(T1 and T3) was significantly different (P＜0.05),but there 's same level in patients with the different pathological N stages(P＞0.05). Conclusion: Preoperative detection of the serum concentration of CEA and CYFRA21-1 has important clinical significance on the accurate judgment of tumor staging in patients with non-small cell lung cancer.

Key words: non-small lung cancer, pathological staging, carcinoembryonie antigen, cytokeratin 19 fragements, neu-ron-specific enolase